SPID

PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA

Retrieved on: 
Monday, April 29, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Pathfinder, Bone marrow, PPI, Nature Biomedical Engineering, BCL2, SPID, Proteomics, Collection, Seoul National University, AML, Prescription, Disease, Family, Acute myeloid leukemia, Patient, Interaction, Biology, Biomarker, Drug development, Medical device

PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx.

Key Points: 
  • PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx.
  • Starting in May, PROTEINA will transport its Pi-View analysis device and related reagents to labs at Emory.
  • PROTEINA and Dr. Woo’s research team will analyze these samples using the PPI PathFinder BCL2 Dx to validate its clinical efficacy.
  • PROTEINA’s CEO, Tae-Young Yoon, remarked, “Having successfully completed domestic clinical validation in South Korea over the past two years, we are very excited about this large-scale clinical validation in the United States.

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

Retrieved on: 
Thursday, September 7, 2023
HTN, AE, Lidocaine, OAK, Oxycodone, Aes, Clinical trial, ECG, Capsaicin, Bankruptcy, Female, Pain, Hypertension, SPID, SAE, Patient, Standard of care, WOMAC, KOOS, SAN, OTC, Hydromorphone, BMI, FDA, Therapy, Triamcinolone acetonide, RTX, Safety, Pharmaceutical industry, Birth control

RTX 20mcg and 12.5mcg have been selected as the clinically optimal and minimally effective doses for further phase 2 pivotal or phase 3 trials.

Key Points: 
  • RTX 20mcg and 12.5mcg have been selected as the clinically optimal and minimally effective doses for further phase 2 pivotal or phase 3 trials.
  • SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") announced today positive Phase 2a top-line clinical trial results for the RTX program.
  • A higher proportion of patients responded to treatment with RTX 20mcg than any other treatment group, including Zilretta.
  • The clinical trial confirmed the potential of resiniferatoxin (RTX) in helping patients with moderate to severe osteoarthritis pain for at least 6 months, if not longer.

Marcus Hotels & Resorts Announces Sale of Skirvin Hilton

Retrieved on: 
Friday, December 16, 2022
Other Travel, Commercial Building & Real Estate, Vacation, Lodging, Construction & Property, Destinations, Travel, Marcus Corporation, NYSE, SPID, City, Partnership, Miller, Security (finance), Steakhouse, Sale, Westmont Hospitality Group, Growth, Food, FRHI Hotels & Resorts, MCS, Economic development, Hotel, Twitter, Skirvin Hilton Hotel

Marcus® Hotels & Resorts , a nationally recognized owner and management company and division of The Marcus Corporation (NYSE: MCS), together with its co-owners, Skirvin Partners in Development (SPID), today announced the sale of the Skirvin Hilton in Oklahoma City to Skirvin Hotel LLC for $36.75 million.

Key Points: 
  • Marcus® Hotels & Resorts , a nationally recognized owner and management company and division of The Marcus Corporation (NYSE: MCS), together with its co-owners, Skirvin Partners in Development (SPID), today announced the sale of the Skirvin Hilton in Oklahoma City to Skirvin Hotel LLC for $36.75 million.
  • After closing in 1988, a public-private partnership between the City of Oklahoma City, Marcus Hotels & Resorts and SPID was formed to bring the Skirvin back to its historic traditions of elegancy and luxury.
  • Marcus Hotels & Resorts owns and/or manages 16 hotels, resorts and other properties in the U.S.
  • The company’s distinctive portfolio includes city-center meeting hotels, upscale resorts, historic properties, and premium branded and independent first-class hotels.

Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain

Retrieved on: 
Thursday, March 31, 2022
FDA, Other Health, Health, Pharmaceutical, Clinical Trials, Private Securities Litigation Reform Act, Vomiting, Duchenne, LinkedIn, Headache, University, Lists of diseases, CF, Hydrocodone, Clinical trial, Cedars-Sinai Medical Center, Annual report, Duchenne muscular dystrophy, Dizziness, Research, Pain, Medical Affairs Bureau, Consultant, Program, Incidence, Cystic fibrosis, U.S. Securities and Exchange Commission, Nausea, Pain management, Peripheral nervous system, SPID, Beta thalassemia, POC, Safety, Biology, Twitter, University of Texas Southwestern Medical Center, Șaeș, Constipation, Sickle cell disease, YouTube, Department, Neuropathic pain, AES, NAV, Instagram, Patient, Security (finance), Pharmaceutical industry, Innovation district, Science, Vertex, Anesthesiology, Facebook, THE PHASE 2 STUDY IN PATIENTS UNDERGOING BUNIONECTOMY, THE PHASE 2 STUDY IN PATIENTS UNDERGOING ABDOMINOPLASTY, VX-548

Two patients in the mid-dose VX-548 arm discontinued treatment due to AEs, none of which were related to treatment.

Key Points: 
  • Two patients in the mid-dose VX-548 arm discontinued treatment due to AEs, none of which were related to treatment.
  • The remarkable consistency in the safety, tolerability and efficacy results in these two studies demonstrate the potential of VX-548 to be a first-in-class non-opioid treatment for acute pain.
  • NaV1.8 is a genetically validated target for the treatment of pain, and Vertex has previously demonstrated clinical proof-of-concept with a small molecule investigational treatment targeting NaV1.8 in multiple pain indications including acute pain, neuropathic pain and musculoskeletal pain.
  • Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

ZENBRIDGE, Developed by Dyne.org, RIDDLE&CODE and InfoCert, Selected for Phase 2 of the European Blockchain Pre-Commercial Procurement

Retrieved on: 
Thursday, March 17, 2022
Software, Networks, Internet, Finance, Hardware, Professional Services, Technology, Security, Ethereum, Bitcoin, ICT, Distributed ledger technology law, GDPR, Gaps, Solution, 2004 Wien Energie Grand Prix, High-velocity cloud, EBP, Internet of things, Automation, Multimedia, CODE, Daimler Mobility, Digital identity, Compliance, IOT, Agid, Digital signature, BMW, Chief innovation officer, Founder, Hyperledger, CTO, Digital, Research, Privacy, Certification, Motion, SPID, Science and technology in Asia, European Commission, Industry, Blockchain, Royal commission, Cryptocurrency, EU, European, RIDDLE&CODE, InfoCert, RIDDLE&CODE, INFOCERT

View the full release here: https://www.businesswire.com/news/home/20220317005181/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220317005181/en/
    Led by the European Commission and 29 member countries that collaborate as a European Blockchain Partnership (EBP), EBSI aims to develop highly secure and compliant cross-border public services on a European level.
  • This involves overcoming gaps in the existing blockchain applications and delivering more demanding solutions that reduce environmental footprint and comply with EU legal frameworks such as the GDPR.
  • The second phase of the project was launched on December 20, 2021, and will run until the end of June 2022.
  • The company develops hardware and software stacks that combine the security of smart cards with blockchain and the Internet of Things (IoT).

DGAP-News: Evonik Industries and Laxxon Medical see future in 3D screen printed pharmaceuticals

Retrieved on: 
Tuesday, March 8, 2022
Screen, NASDAQ, IPO, EVC, Tablet, Risk, NY, Investment, SPID, Chemistry, NEW, EBITDA, Health, Polymer, Patient, Technology, Solution, 3D, Material, Printing, Nutrition, Accuro Healthcare Solutions, Patent, Fine chemical, 3D printing, Thermoplastic, Pharmaceutical industry, Evonik Venture Capital, Evonik Industries, Laxxon Medical Corporation, Evonik Venture Capital, Evonik Industries, Laxxon Medical Corporation, EVONIK VENTURE CAPITAL, EVONIK INDUSTRIES, LAXXON MEDICAL CORPORATION

Laxxon Medical is a U.S. based company whose patented 3D screen printing technology enables the controlled release of multiple active pharmaceutical ingredients within a single tablet.

Key Points: 
  • Laxxon Medical is a U.S. based company whose patented 3D screen printing technology enables the controlled release of multiple active pharmaceutical ingredients within a single tablet.
  • In addition to the investment of an undisclosed amount, Evonik and Laxxon Medical have concluded a joint product development and cooperation agreement.
  • According to the agreement, Evonik will manufacture tablets with Laxxon Medical's 3D screen printing technology.
  • Laxxon Medical holds the exclusive worldwide rights to the patented use and application of 3D screen printing technology for the development, manufacture, and commercialization of pharmaceutical dosage forms.

Woolpert Opens Maritime, Defense Technology and Geospatial Intelligence Office in St. Pete Innovation District

Retrieved on: 
Wednesday, March 2, 2022
AAM, Research, Industry, View, Hub, Government, Organization, Federation, Solution, Culture, AEG, Architecture, Growth, Multimedia, Entrepreneurship, Economic development, Patent, Learning, ENR, Engineering, Education, Partnership, Collection, SPID, Airline, Management

ST. PETERSBURG, Fla., March 2, 2022 /PRNewswire/ -- Woolpert has opened an office in St. Petersburg, Fla., that will focus on maritime, defense technology and geospatial intelligence.

Key Points: 
  • ST. PETERSBURG, Fla., March 2, 2022 /PRNewswire/ -- Woolpert has opened an office in St. Petersburg, Fla., that will focus on maritime, defense technology and geospatial intelligence.
  • The office is located in the St. Pete Innovation District ( SPID ) and is part of its new St. Petersburg Maritime and Defense Technology Hub, which is holding its ribbon-cutting event today.
  • Its Maritime and Defense Technology Hub assembles innovators from industry, government and academic organizations that can utilize state and federal funding to advance critical marine science and defense technology solutions.
  • The international architecture, engineering and geospatial (AEG) firm specializes in delivering geospatial data and innovative hybrid technologies to defense and federal intelligence communities.

DGAP-News: 'Game Changing' Technology Enables QR Code Integration with 3D Screen Printing

Retrieved on: 
Thursday, February 17, 2022
Drug, NY, API, Counterfeit, NEW, Doctor of Philosophy, CSO, VTT Technical Research Centre of Finland, Technology, Approximation error, Science, QR, 3D, Screen, Patient safety, SPID, Medical device, 3D printing

The study investigates the progress that has been made in using QR codes for drug labeling, with a specific focus on the potential for using 3D screen printing to expedite QR code integration at the single tablet level.

Key Points: 
  • The study investigates the progress that has been made in using QR codes for drug labeling, with a specific focus on the potential for using 3D screen printing to expedite QR code integration at the single tablet level.
  • Laxxon Medical Corp. holds the exclusive worldwide license to explore this 3DSP technology for all pharmaceutical applications.
  • "Using this approach, the QR code is part of a one-stop manufacturing process of the tablet," said corresponding author Achim Schneeberger, PhD, CSO of Laxxon Medical.
  • Laxxon Medical holds exclusive worldwide rights to the patented use and application of 3D screen printing technology for the development, manufacture, and commercialization of pharmaceutical dosage forms.

Dyne.org, RIDDLE&CODE and InfoCert's Consortium Appointed to Take EBSI to the Next Level

Retrieved on: 
Tuesday, September 21, 2021
Professional Services, Data Management, Security, Technology, Software, Finance, Internet, Ethereum, Bitcoin, Crypto, Adoption, Smart city, Hyperledger, ISO, Language, Policy, CTO, Digital Trust Center, SPID, BMW, Solution, Daimler Mobility, Chief innovation officer, Privacy, Executive Vice President of the European Commission for A Europe Fit for the Digital Age, Multimedia, CODE, Service provider, Trust, Freedom, Energy policy of the European Union, Internet of things, European Union, IOT, Digital identity, Founder, Certificate authority, Blockchain, Digital, Agid, European Commission, Digital signature, 2004 Wien Energie Grand Prix, H2020, EIDAS, Citizenship, Web browser, Science and technology in Asia, Certification, Produce traceability, Cryptocurrency, RIDDLE&CODE, Dyne.org, InfoCert, RIDDLE&CODE, DYNE.ORG, INFOCERT

The European Commission's vision for EBSI is to leverage distributed ledger technologies to create international and intra-communautaire services for public administrations.

Key Points: 
  • The European Commission's vision for EBSI is to leverage distributed ledger technologies to create international and intra-communautaire services for public administrations.
  • The blockchain-agnostic solution offers compatibility with a wide range of products to grant freedom of choice to participating member states and solution developers.
  • Dr. Francesca Bria , president of the Italian National Innovation Fund Cassa Depositi e Prestiti comments: "Zenroom stands for Citizen Crypto.
  • For the initial phase of EBSI's procurement, the consortium proposes a revolutionary solution for a European Digital Product Passport .